                               SEQUENCE LISTING

<110> DANA-FARBER CANCER INSTITUTE, INC.
 
<120> STABILIZED PEPTIDE-MEDIATED TARGETED PROTEIN DEGRADATION

<130> 00530-0343WO1

<140> PCT/US2018/065784
<141> 2018-12-14

<150> 62/599,608
<151> 2017-12-15

<160> 145   

<170> PatentIn version 3.5

<210> 1
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source 
<223> /note="May be N-term Acetylated"

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Thalidomide-aminohexanoic 

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (13)..(13)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (14)..(14)
<223> Norleucine 

<220>
<221> MOD_RES
<222> (17)..(17)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (26)..(26)
<223> Lys-degron

<220>
<221> VARIANT
<222> (26)..(26)
<223> /replace=" "

<220>
<221> SITE
<222> (1)..(26)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 1
Xaa Gln Trp Ala Arg Glu Ile Gly Ala Gln Leu Arg Xaa Xaa Ala Asp 
1               5                   10                  15      


Xaa Leu Asn Ala Gln Tyr Glu Arg Arg Xaa 
            20                  25      


<210> 2
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source 
<223> /note="May be N-term Acetylated"

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Thalidomide-aminohexanoic 

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Degron-Ahx" or " "

<220>
<221> MOD_RES
<222> (7)..(7)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (29)..(29)
<223> Lys-degron

<220>
<221> VARIANT
<222> (29)..(29)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 2
Xaa Phe Ser Ser Asn Arg Xaa Lys Ile Leu Xaa Arg Thr Gln Ile Leu 
1               5                   10                  15      


Asn Gln Glu Trp Lys Gln Arg Arg Ile Gln Pro Val Xaa 
            20                  25                  


<210> 3
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source 
<223> /note="May be N-term Acetylated"

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Thalidomide-aminohexanoic 

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Degron-Ahx" or " "

<220>
<221> MOD_RES
<222> (8)..(8)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (12)..(12)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys-degron

<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(20)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 3
Xaa Arg Arg Phe Phe Gly Ile Xaa Leu Thr Asn Xaa Leu Lys Thr Glu 
1               5                   10                  15      


Glu Gly Asn Xaa 
            20  


<210> 4
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source 
<223> /note="May be N-term Acetylated"

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Thalidomide-aminohexanoic 

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (16)..(16)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (20)..(20)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys-degron

<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace=" "

<220>
<221> SITE
<222> (1)..(24)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 4
Xaa Arg Lys Ala Leu Glu Thr Leu Arg Arg Val Gly Asp Gly Val Xaa 
1               5                   10                  15      


Arg Asn His Xaa Thr Ala Phe Xaa 
            20                  


<210> 5
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source 
<223> /note="May be N-term Acetylated"

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Thalidomide-aminohexanoic 

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Degron-Ahx" or " "

<220>
<221> MOD_RES
<222> (15)..(15)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (19)..(19)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Norleucine 

<220>
<221> MOD_RES
<222> (26)..(26)
<223> Lys-degron

<220>
<221> VARIANT
<222> (26)..(26)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(26)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 5
Xaa Leu Ser Gln Glu Gln Leu Glu His Arg Glu Arg Ser Leu Xaa Thr 
1               5                   10                  15      


Leu Arg Xaa Ile Gln Arg Xaa Leu Phe Xaa 
            20                  25      


<210> 6
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source 
<223> /note="May be N-term Acetylated"

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Thalidomide-aminohexanoic 

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (5)..(5)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> Cyclobutylalanine 

<220>
<221> MOD_RES
<222> (12)..(12)
<223> S-pentenyl alanine 

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Lys-degron

<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace=" "

<220>
<221> SITE
<222> (1)..(16)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 6
Xaa Leu Thr Phe Xaa Glu Tyr Trp Ala Gln Xaa Xaa Ser Ala Ala Xaa 
1               5                   10                  15      


<210> 7
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source 
<223> /note="May be N-term Acetylated"

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Thalidomide-aminohexanoic 

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (13)..(13)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (17)..(17)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Norleucine 

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Lys-degron

<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace=" "

<220>
<221> SITE
<222> (1)..(23)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 7
Xaa Asp Ile Ile Arg Asn Ile Ala Arg His Leu Ala Xaa Val Gly Asp 
1               5                   10                  15      


Xaa Xaa Asp Arg Ser Ile Xaa 
            20              


<210> 8
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source 
<223> /note="May be N-term Acetylated"

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Thalidomide-aminohexanoic 

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (10)..(10)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (14)..(14)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Lys-degron

<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace=" "

<220>
<221> SITE
<222> (1)..(23)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 8
Xaa Ile Trp Ile Ala Gln Glu Leu Arg Xaa Ile Gly Asp Xaa Phe Asn 
1               5                   10                  15      


Ala Tyr Tyr Ala Arg Arg Xaa 
            20              


<210> 9
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source 
<223> /note="May be N-term Acetylated"

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Thalidomide-aminohexanoic 

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (15)..(15)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Norleucine 

<220>
<221> MOD_RES
<222> (19)..(19)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (27)..(27)
<223> Lys-degron

<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace=" "

<220>
<221> SITE
<222> (1)..(27)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 9
Xaa Asn Leu Trp Ala Ala Gln Arg Tyr Gly Arg Glu Leu Arg Xaa Xaa 
1               5                   10                  15      


Asp Asp Xaa Phe Val Asp Ser Phe Lys Lys Xaa 
            20                  25          


<210> 10
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source 
<223> /note="May be N-term Acetylated"

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Thalidomide-aminohexanoic 

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Degron-Ahx" or " "

<220>
<221> MOD_RES
<222> (15)..(15)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Norleucine 

<220>
<221> MOD_RES
<222> (19)..(19)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (27)..(27)
<223> Lys-degron

<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(27)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 10
Xaa Asn Leu Trp Ala Ala Gln Arg Tyr Gly Arg Glu Leu Arg Xaa Xaa 
1               5                   10                  15      


Ser Asp Xaa Phe Val Asp Ser Phe Lys Lys Xaa 
            20                  25          


<210> 11
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source 
<223> /note="May be N-term Acetylated"

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Thalidomide-aminohexanoic 

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Degron-Ahx" or " "

<220>
<221> MOD_RES
<222> (10)..(10)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (14)..(14)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (20)..(20)
<223> Norleucine 

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Lys-degron

<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(23)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 11
Xaa Gln Leu Thr Ala Ala Arg Leu Lys Xaa Leu Gly Asp Xaa Leu His 
1               5                   10                  15      


Gln Arg Thr Xaa Trp Arg Xaa 
            20              


<210> 12
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source 
<223> /note="May be N-term Acetylated"

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Thalidomide-aminohexanoic 

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (14)..(14)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (18)..(18)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (27)..(27)
<223> Lys-degron

<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace=" "

<220>
<221> SITE
<222> (1)..(27)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 12
Xaa Ala Glu Leu Glu Val Glu Ser Ala Thr Gln Leu Arg Xaa Phe Gly 
1               5                   10                  15      


Asp Xaa Leu Asn Phe Arg Gln Lys Leu Leu Xaa 
            20                  25          


<210> 13
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Degron-Ahx

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (13)..(13)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (14)..(14)
<223> Norleucine 

<220>
<221> MOD_RES
<222> (17)..(17)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (26)..(26)
<223> Lys-epsilon-amino-thalidomide 

<220>
<221> VARIANT
<222> (26)..(26)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(26)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 13
Xaa Gln Trp Ala Arg Glu Ile Gly Ala Gln Leu Arg Xaa Xaa Ala Asp 
1               5                   10                  15      


Xaa Leu Asn Ala Gln Tyr Glu Arg Arg Xaa 
            20                  25      


<210> 14
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Degron-Ahx

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (7)..(7)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (29)..(29)
<223> Lys-epsilon-amino-thalidomide 

<220>
<221> VARIANT
<222> (29)..(29)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(29)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 14
Xaa Phe Ser Ser Asn Arg Xaa Lys Ile Leu Xaa Arg Thr Gln Ile Leu 
1               5                   10                  15      


Asn Gln Glu Trp Lys Gln Arg Arg Ile Gln Pro Val Xaa 
            20                  25                  


<210> 15
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Degron-Ahx

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (8)..(8)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (12)..(12)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys-epsilon-amino-thalidomide 

<220>
<221> VARIANT
<222> (20)..(20)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(20)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 15
Xaa Arg Arg Phe Phe Gly Ile Xaa Leu Thr Asn Xaa Leu Lys Thr Glu 
1               5                   10                  15      


Glu Gly Asn Xaa 
            20  


<210> 16
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Degron-Ahx

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (16)..(16)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (20)..(20)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (24)..(24)
<223> Lys-epsilon-amino-thalidomide 

<220>
<221> VARIANT
<222> (24)..(24)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(24)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 16
Xaa Arg Lys Ala Leu Glu Thr Leu Arg Arg Val Gly Asp Gly Val Xaa 
1               5                   10                  15      


Arg Asn His Xaa Thr Ala Phe Xaa 
            20                  


<210> 17
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Degron-Ahx

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (15)..(15)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (19)..(19)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Norleucine 

<220>
<221> MOD_RES
<222> (26)..(26)
<223> Lys-epsilon-amino-thalidomide 

<220>
<221> VARIANT
<222> (26)..(26)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(26)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 17
Xaa Leu Ser Gln Glu Gln Leu Glu His Arg Glu Arg Ser Leu Xaa Thr 
1               5                   10                  15      


Leu Arg Xaa Ile Gln Arg Xaa Leu Phe Xaa 
            20                  25      


<210> 18
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Degron-Ahx

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (5)..(5)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> Cyclobutylalanine 

<220>
<221> MOD_RES
<222> (12)..(12)
<223> S-pentenyl alanine 

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Lys-epsilon-amino-thalidomide 

<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(16)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 18
Xaa Leu Thr Phe Xaa Glu Tyr Trp Ala Gln Xaa Xaa Ser Ala Ala Xaa 
1               5                   10                  15      


<210> 19
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Degron-Ahx

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (13)..(13)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (17)..(17)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Norleucine 
 
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Lys-epsilon-amino-thalidomide 

<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(23)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 19
Xaa Asp Ile Ile Arg Asn Ile Ala Arg His Leu Ala Xaa Val Gly Asp 
1               5                   10                  15      


Xaa Xaa Asp Arg Ser Ile Xaa 
            20              


<210> 20
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Degron-Ahx

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (10)..(10)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (14)..(14)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Lys-epsilon-amino-thalidomide 

<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(23)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 20
Xaa Ile Trp Ile Ala Gln Glu Leu Arg Xaa Ile Gly Asp Xaa Phe Asn 
1               5                   10                  15      


Ala Tyr Tyr Ala Arg Arg Xaa 
            20              


<210> 21
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Degron-Ahx

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (15)..(15)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Norleucine 
 
<220>
<221> MOD_RES
<222> (19)..(19)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (27)..(27)
<223> Lys-epsilon-amino-thalidomide 

<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(27)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 21
Xaa Asn Leu Trp Ala Ala Gln Arg Tyr Gly Arg Glu Leu Arg Xaa Xaa 
1               5                   10                  15      


Asp Asp Xaa Phe Val Asp Ser Phe Lys Lys Xaa 
            20                  25          


<210> 22
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Degron-Ahx

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (15)..(15)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Norleucine 
 
<220>
<221> MOD_RES
<222> (19)..(19)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (27)..(27)
<223> Lys-epsilon-amino-thalidomide 

<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(27)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 22
Xaa Asn Leu Trp Ala Ala Gln Arg Tyr Gly Arg Glu Leu Arg Xaa Xaa 
1               5                   10                  15      


Ser Asp Xaa Phe Val Asp Ser Phe Lys Lys Xaa 
            20                  25          


<210> 23
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Degron-Ahx

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (10)..(10)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (14)..(14)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (20)..(20)
<223> Norleucine 
 
<220>
<221> MOD_RES
<222> (23)..(23)
<223> Lys-epsilon-amino-thalidomide 

<220>
<221> VARIANT
<222> (23)..(23)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(23)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 23
Xaa Gln Leu Thr Ala Ala Arg Leu Lys Xaa Leu Gly Asp Xaa Leu His 
1               5                   10                  15      


Gln Arg Thr Xaa Trp Arg Xaa 
            20              


<210> 24
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Degron-Ahx

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (14)..(14)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (18)..(18)
<223> S-pentenyl alanine or any amino acid 

<220>
<221> MOD_RES
<222> (27)..(27)
<223> Lys-epsilon-amino-thalidomide 

<220>
<221> VARIANT
<222> (27)..(27)
<223> /replace="Lys-ivDde" or " "

<220>
<221> SITE
<222> (1)..(27)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 24
Xaa Ala Glu Leu Glu Val Glu Ser Ala Thr Gln Leu Arg Xaa Phe Gly 
1               5                   10                  15      


Asp Xaa Leu Asn Phe Arg Gln Lys Leu Leu Xaa 
            20                  25          


<210> 25
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 25
Asp Gln Ile Val Pro Glu Tyr 
1               5           


<210> 26
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 26
Gly Phe Asp Val Pro Asp 
1               5       


<210> 27
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 27
Gly Phe Asp Ala Ala Asp 
1               5       


<210> 28
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 28
Gly Asn Asp Val Pro Asp 
1               5       


<210> 29
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 29
Pro Gln Thr Val Pro Asp 
1               5       


<210> 30
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 30
Asp Gln Ile Val Pro Asp 
1               5       


<210> 31
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 31
Phe Ser Asp Leu Trp Lys Leu Leu 
1               5               


<210> 32
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 32
Ser Val Glu Gln Thr Pro Lys Lys 
1               5               


<210> 33
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 33
Leu Leu Pro Thr Pro Pro Leu Ser 
1               5               


<210> 34
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 34
Ala Ser Ser Ser Ser 
1               5   


<210> 35
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 35
Leu Ala Pro Ala Ala Gly Asp Thr Ile Ile Ser Leu Asp Phe 
1               5                   10                  


<210> 36
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 36
Pro Phe Leu Thr Pro Ser Pro Glu 
1               5               


<210> 37
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 37
Pro Pro Pro Tyr 
1               


<210> 38
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 38
Asp Glu Glu Thr Gly Glu 
1               5       


<210> 39
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 39
Gln Asp Ile Asp Leu Gly Val 
1               5           


<210> 40
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 40
Leu Leu Gln Pro Asn Asn Tyr Gln Phe Cys 
1               5                   10  


<210> 41
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 41
Arg Ala Val Glu Asn Gln Tyr Ser Phe Tyr 
1               5                   10  


<210> 42
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 42
Gln Lys Glu Asn Ser 
1               5   


<210> 43
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 43
Phe Asp Ile Tyr Met Asp 
1               5       


<210> 44
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 44
Pro Arg Thr Ala Leu Gly Asp Ile Gly 
1               5                   


<210> 45
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 45
Asp Lys Glu Asn Gly 
1               5   


<210> 46
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Phospho-Ser 

<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="phospho-Thr"

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Any amino acid

<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="phospho-Ser" or "phospho-Thr"

<220>
<221> SITE
<222> (1)..(5)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 46
Ser Pro Xaa Xaa Glu 
1               5   


<210> 47
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 47
Gly Gly Gly Ser 
1               


<210> 48
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 48
Ser Gly Gly Gly 
1               


<210> 49
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 49
Gly Gly Gly Gly Ser 
1               5   


<210> 50
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 50
Ser Gly Gly Gly Gly 
1               5   


<210> 51
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 51
Gly Gly Gly Gly Gly Ser 
1               5       


<210> 52
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 52
Ser Gly Gly Gly Gly Gly 
1               5       


<210> 53
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 53
Gly Gly Gly Gly Gly Gly Ser 
1               5           


<210> 54
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 54
Ser Gly Gly Gly Gly Gly Gly 
1               5           


<210> 55
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(5)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (9)..(10)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (14)..(15)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (19)..(20)
<223> Any amino acid

<220>
<221> SITE
<222> (1)..(20)
<223> /note="This region may encompass 0-4 'Gly Gly Gly Xaa Xaa'
      repeating units"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 55
Gly Gly Gly Xaa Xaa Gly Gly Gly Xaa Xaa Gly Gly Gly Xaa Xaa Gly 
1               5                   10                  15      


Gly Gly Xaa Xaa Gly Gly Gly Gly Ser 
            20                  25  


<210> 56
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (6)..(6)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (11)..(11)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (21)..(21)
<223> Any amino acid

<220>
<221> SITE
<222> (6)..(25)
<223> /note="This region may encompass 0-4 'Xaa Gly Gly Gly Ser'
      repeating units"

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 56
Gly Gly Gly Gly Ser Xaa Gly Gly Gly Ser Xaa Gly Gly Gly Ser Xaa 
1               5                   10                  15      


Gly Gly Gly Ser Xaa Gly Gly Gly Ser 
            20                  25  


<210> 57
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> SITE
<222> (1)..(20)
<223> /note="This region may encompass 0-4 'Gly Gly Gly Pro Ser'
      repeating units"

<400> 57
Gly Gly Gly Pro Ser Gly Gly Gly Pro Ser Gly Gly Gly Pro Ser Gly 
1               5                   10                  15      


Gly Gly Pro Ser Gly Gly Gly Gly Ser 
            20                  25  


<210> 58
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> SITE
<222> (1)..(20)
<223> /note="This region may encompass 0-4 'Gly Gly Gly Gly Gln'
      repeating units"

<400> 58
Gly Gly Gly Gly Gln Gly Gly Gly Gly Gln Gly Gly Gly Gly Gln Gly 
1               5                   10                  15      


Gly Gly Gly Gln Gly Gly Gly Gly Ser 
            20                  25  


<210> 59
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> SITE
<222> (1)..(20)
<223> /note="This region may encompass 0-4 'Gly Gly Gly Gly Ala'
      repeating units"

<400> 59
Gly Gly Gly Gly Ala Gly Gly Gly Gly Ala Gly Gly Gly Gly Ala Gly 
1               5                   10                  15      


Gly Gly Gly Ala Gly Gly Gly Gly Ser 
            20                  25  


<210> 60
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> SITE
<222> (6)..(25)
<223> /note="This region may encompass 0-4 'Pro Gly Gly Gly Ser'
      repeating units"

<400> 60
Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Pro Gly Gly Gly Ser Pro 
1               5                   10                  15      


Gly Gly Gly Ser Pro Gly Gly Gly Ser 
            20                  25  


<210> 61
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 61
Gly Gly Gly Gly Ala Gly Gly Gly Gly Ala Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210> 62
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 62
Gly Gly Gly Gly Gln Gly Gly Gly Gly Gln Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210> 63
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 63
Gly Gly Gly Pro Ser Gly Gly Gly Pro Ser Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210> 64
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 64
Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Pro Gly Gly Gly Ser 
1               5                   10                  15  


<210> 65
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Any amino acid

<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Ile" or "Val" or "Met"

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Any amino acid

<220>
<221> SITE
<222> (1)..(9)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 65
Xaa Arg Xaa Xaa Leu Xaa Xaa Leu Xaa 
1               5                   


<210> 66
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Any amino acid

<400> 66
Xaa Lys Glu Asn Xaa 
1               5   


<210> 67
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Ile" or "Val" or "Leu"

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Any amino acid

<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Leu" or "Met" or "Val" or "Pro"

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="His" or "Tyr"

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Any amino acid

<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Glu"

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Any amino acid

<220>
<221> SITE
<222> (7)..(9)
<223> /note="This region may encompass 0-3 residues"

<220>
<221> VARIANT
<222> (10)..(10)
<223> /replace="Glu" or "Ser" or "Thr"

<220>
<221> SITE
<222> (1)..(10)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 67
Phe Xaa Ile Phe Xaa Asp Xaa Xaa Xaa Asp 
1               5                   10  


<210> 68
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Any amino acid

<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Leu" or "Met"

<220>
<221> SITE
<222> (1)..(3)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 68
Xaa Ile Arg 
1           


<210> 69
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Asn"

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Any amino acid

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Thr"

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Any amino acid

<220>
<221> SITE
<222> (1)..(7)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 69
Asp Xaa Tyr Ser Xaa Xaa Pro 
1               5           


<210> 70
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 70
Asp Tyr Arg 
1           


<210> 71
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Glu"

<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Glu"

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Any amino acid

<220>
<221> SITE
<222> (3)..(5)
<223> /note="This region may encompass 2-3 residues"

<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Glu"

<220>
<221> SITE
<222> (1)..(8)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 71
Asp Asp Xaa Xaa Xaa Val Pro Asp 
1               5               


<210> 72
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Gln" or " "

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Leu" or "Met" or "Val"

<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Thr"

<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Glu" or "Asn"

<220>
<221> VARIANT
<222> (7)..(7)
<223> /replace="Tyr"

<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Tyr"

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (10)..(10)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (11)..(11)
<223> Any amino acid

<220>
<221> SITE
<222> (9)..(11)
<223> /note="This region may encompass 2-3 residues"

<220>
<221> VARIANT
<222> (12)..(12)
<223> /replace="Arg"

<220>
<221> VARIANT
<222> (13)..(13)
<223> /replace="Arg"

<220>
<221> VARIANT
<222> (14)..(14)
<223> /replace="Arg"

<220>
<221> SITE
<222> (12)..(14)
<223> /note="This region may encompass 2-3 residues"

<220>
<221> MOD_RES
<222> (15)..(15)
<223> Any amino acid except Asp or Glu

<220>
<221> SITE
<222> (1)..(15)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 72
Asn Xaa Xaa Ile Ser Asp Phe Phe Xaa Xaa Xaa Lys Lys Lys Xaa 
1               5                   10                  15  


<210> 73
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Gln" or " "

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Leu" or "Met" or "Val"

<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Glu" or "Asn"

<220>
<221> VARIANT
<222> (7)..(7)
<223> /replace="Met" or "Phe" or "Tyr"

<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Met" or "Tyr"

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (10)..(10)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (11)..(11)
<223> Any amino acid

<220>
<221> SITE
<222> (9)..(11)
<223> /note="This region may encompass 2-3 residues"

<220>
<221> VARIANT
<222> (12)..(12)
<223> /replace="Arg"

<220>
<221> VARIANT
<222> (13)..(13)
<223> /replace="Arg"

<220>
<221> VARIANT
<222> (14)..(14)
<223> /replace="Arg"

<220>
<221> SITE
<222> (12)..(14)
<223> /note="This region may encompass 2-3 residues"

<220>
<221> MOD_RES
<222> (15)..(15)
<223> Any amino acid except Asp or Glu

<220>
<221> SITE
<222> (1)..(15)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 73
Asn Xaa Xaa Ile Thr Asp His Phe Xaa Xaa Xaa Lys Lys Lys Xaa 
1               5                   10                  15  


<210> 74
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Asn" or "Ser"

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Any amino acid

<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Glu" or "Ser"

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Asn" or "Ser"

<220>
<221> SITE
<222> (1)..(6)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 74
Asp Xaa Asp Thr Gly Glu 
1               5       


<210> 75
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid

<400> 75
Gln Asp Xaa Asp Leu Gly Val 
1               5           


<210> 76
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Pro"

<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Val"

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Met"

<220>
<221> SITE
<222> (1)..(5)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 76
Ala Pro Met Ile Val 
1               5   


<210> 77
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (2)..(2)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Any amino acid

<220>
<221> VARIANT
<222> (7)..(7)
<223> /replace="Val"

<220>
<221> SITE
<222> (1)..(10)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 77
Glu Xaa Glu Glu Xaa Glu Ala Asp Gln His 
1               5                   10  


<210> 78
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (2)..(2)
<223> Any amino acid except Pro

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid except Pro

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Any amino acid except Pro

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Any amino acid except Pro

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Any amino acid except Pro

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Any amino acid except Pro

<220>
<221> SITE
<222> (6)..(8)
<223> /note="This region may encompass 2-3 residues"

<220>
<221> VARIANT
<222> (9)..(9)
<223> /replace="Ile" or "Leu"

<220>
<221> SITE
<222> (1)..(9)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 78
Phe Xaa Xaa Xaa Trp Xaa Xaa Xaa Val 
1               5                   


<210> 79
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Tyr" or "Leu" or "Ile" or "Trp"

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid except Pro

<220>
<221> SITE
<222> (1)..(3)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 79
Met Phe Xaa 
1           


<210> 80
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Lys"

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid except Pro

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Any amino acid

<220>
<221> SITE
<222> (1)..(4)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 80
Met Arg Xaa Xaa 
1               


<210> 81
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Asp"

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid

<220>
<221> SITE
<222> (1)..(3)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 81
Met Glu Xaa 
1           


<210> 82
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Gln"

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid

<220>
<221> SITE
<222> (1)..(3)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 82
Met Asn Xaa 
1           


<210> 83
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace=" "

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid

<220>
<221> SITE
<222> (1)..(3)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 83
Met Cys Xaa 
1           


<210> 84
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Leu"

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (10)..(10)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (11)..(11)
<223> Any amino acid

<220>
<221> SITE
<222> (4)..(11)
<223> /note="This region may encompass 6-8 residues"

<220>
<221> VARIANT
<222> (12)..(12)
<223> /replace="Leu" or "Ile" or "Val" or "Met"

<220>
<221> MOD_RES
<222> (13)..(13)
<223> Any amino acid

<220>
<221> VARIANT
<222> (14)..(14)
<223> /replace="Leu" or "Ile" or "Val" or "Met"

<220>
<221> SITE
<222> (1)..(14)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 84
Ile Ala Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Phe 
1               5                   10                  


<210> 85
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Any amino acid

<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Lys"

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Lys"

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Any amino acid

<220>
<221> VARIANT
<222> (11)..(11)
<223> /replace="Leu" or "Met"

<220>
<221> MOD_RES
<222> (12)..(12)
<223> Any amino acid

<220>
<221> VARIANT
<222> (13)..(13)
<223> /replace="Lys"

<220>
<221> VARIANT
<222> (15)..(15)
<223> /replace="Arg" or "Lys"

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Any amino acid

<220>
<221> VARIANT
<222> (17)..(17)
<223> /replace="Lys"

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Any amino acid

<220>
<221> SITE
<222> (1)..(18)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 85
Xaa Xaa Arg Arg Xaa Ser Leu Xaa Xaa Phe Phe Xaa Arg Arg His Xaa 
1               5                   10                  15      


Arg Xaa 
        


<210> 86
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Ile" or "Val" or "Met" or "Pro"

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid

<220>
<221> SITE
<222> (2)..(3)
<223> /note="This region may encompass 0-2 residues"

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Any amino acid

<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Thr"

<220>
<221> SITE
<222> (1)..(8)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 86
Leu Xaa Xaa Thr Pro Xaa Xaa Ser 
1               5               


<210> 87
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Ile" or "Val" or "Met" or "Pro"

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid

<220>
<221> SITE
<222> (2)..(3)
<223> /note="This region may encompass 0-2 residues"

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Any amino acid

<220>
<221> SITE
<222> (1)..(8)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 87
Leu Xaa Xaa Thr Pro Xaa Xaa Glu 
1               5               


<210> 88
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Any amino acid

<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Glu"

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Any amino acid

<220>
<221> SITE
<222> (1)..(8)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 88
Xaa Xaa Asp Xaa Thr Pro Xaa Lys 
1               5               


<210> 89
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Any amino acid

<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Leu" or "Ile" or "Ala"

<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Leu" or "Ile"

<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Leu" or "Ile"

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (10)..(10)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (11)..(11)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (13)..(13)
<223> Any amino acid

<220>
<221> SITE
<222> (1)..(13)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 89
Xaa Val Val Gly Trp Pro Pro Val Xaa Xaa Xaa Arg Xaa 
1               5                   10              


<210> 90
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Any amino acid

<220>
<221> SITE
<222> (4)..(6)
<223> /note="This region may encompass 2-3 residues"

<220>
<221> VARIANT
<222> (7)..(7)
<223> /replace="Thr"

<220>
<221> SITE
<222> (1)..(7)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 90
Asp Ser Gly Xaa Xaa Xaa Ser 
1               5           


<210> 91
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Any amino acid except Pro

<400> 91
Xaa Pro Xaa Ala Xaa Val Xaa Pro Xaa 
1               5                   


<210> 92
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Val" or "Pro"

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Any amino acid

<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Thr"

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Thr"

<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Thr"

<220>
<221> SITE
<222> (1)..(5)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 92
Ala Xaa Ser Ser Ser 
1               5   


<210> 93
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 93
His Arg Lys His Leu Gln Glu Ile Pro 
1               5                   


<210> 94
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 94
Ser Lys Glu Asn Val 
1               5   


<210> 95
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 95
Thr Arg Ile Arg 
1               


<210> 96
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 96
Asp Gln Ile Val Pro Glu Tyr 
1               5           


<210> 97
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 97
Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu 
1               5                   10              


<210> 98
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 98
Ser Pro Glu Thr Gly Glu 
1               5       


<210> 99
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 99
Glu Pro Glu Glu Pro Glu Ala Asp Gln His 
1               5                   10  


<210> 100
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 100
Leu Ala Pro Tyr Ile Pro Met Asp Asp Asp Phe Gln Leu 
1               5                   10              


<210> 101
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 101
Leu Thr Pro Pro Gln Ser 
1               5       


<210> 102
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 102
Ser Val Glu Gln Thr Pro Arg Lys 
1               5               


<210> 103
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 103
Asp Ser Gly Asn Tyr Ser 
1               5       


<210> 104
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 104
Lys Pro Ala Ala Val Val Ala Pro Ile 
1               5                   


<210> 105
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 105
Ala Asp Ser Ser Thr 
1               5   


<210> 106
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 106
Leu Thr Pro Pro Ala Ser 
1               5       


<210> 107
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 107
Leu Thr Pro Pro Ser Ser 
1               5       


<210> 108
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 108
Leu Ser Pro Pro Pro Ser 
1               5       


<210> 109
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 109
Leu Ser Pro Pro Ala Ser 
1               5       


<210> 110
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 110
Leu Ser Pro Pro Leu Ser 
1               5       


<210> 111
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 111
Asp Ser Gly Ile Ile Ser 
1               5       


<210> 112
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 112
Asp Ser Gly Asn Tyr Thr 
1               5       


<210> 113
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 113
Asp Ser Gly Ile Asp Thr 
1               5       


<210> 114
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 114
Asp Ser Gly Ile Glu Thr 
1               5       


<210> 115
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 115
Asp Ser Gly Val Asp Thr Ser 
1               5           


<210> 116
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 116
Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Ile 
1               5                   10              


<210> 117
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 117
Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Lys Leu 
1               5                   10              


<210> 118
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 118
Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Ser 
1               5                   10              


<210> 119
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (10)..(10)
<223> Cyclobutylalanine 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> S-pentenyl alanine 

<220>
<221> MOD_RES
<222> (15)..(15)
<223> Aminohexanoic acid 

<220>
<221> MOD_RES
<222> (16)..(16)
<223> Aminohexanoic acid 

<400> 119
Leu Thr Phe Xaa Glu Tyr Trp Ala Gln Xaa Xaa Ser Ala Ala Xaa Xaa 
1               5                   10                  15      


Asp Gln Ile Val Pro Glu Tyr 
            20              


<210> 120
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (10)..(10)
<223> Cyclobutylalanine 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> S-pentenyl alanine 

<220>
<221> MOD_RES
<222> (15)..(15)
<223> Aminohexanoic acid 

<400> 120
Leu Thr Phe Xaa Glu Tyr Trp Ala Gln Xaa Xaa Ser Ala Ala Xaa Asp 
1               5                   10                  15      


Gln Ile Val Pro Glu Tyr 
            20          


<210> 121
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (8)..(8)
<223> Aminohexanoic acid 

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Aminohexanoic acid 

<220>
<221> MOD_RES
<222> (13)..(13)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (19)..(19)
<223> Cyclobutylalanine 

<220>
<221> MOD_RES
<222> (20)..(20)
<223> S-pentenyl alanine 

<400> 121
Asp Gln Ile Val Pro Glu Tyr Xaa Xaa Leu Thr Phe Xaa Glu Tyr Trp 
1               5                   10                  15      


Ala Gln Xaa Xaa Ser Ala Ala 
            20              


<210> 122
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (8)..(8)
<223> Aminohexanoic acid 

<220>
<221> MOD_RES
<222> (12)..(12)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Cyclobutylalanine 

<220>
<221> MOD_RES
<222> (19)..(19)
<223> S-pentenyl alanine 

<400> 122
Asp Gln Ile Val Pro Glu Tyr Xaa Leu Thr Phe Xaa Glu Tyr Trp Ala 
1               5                   10                  15      


Gln Xaa Xaa Ser Ala Ala 
            20          


<210> 123
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"


<220>
<221> MOD_RES
<222> (9)..(9)
<223> S-pentenyl alanine 

<220>
<221> MOD_RES
<222> (13)..(13)
<223> S-pentenyl alanine 

<220>
<221> MOD_RES
<222> (22)..(22)
<223> Aminohexanoic acid 

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Aminohexanoic acid 

<400> 123
Ile Trp Ile Ala Gln Glu Leu Arg Xaa Ile Gly Asp Xaa Phe Asn Ala 
1               5                   10                  15      


Tyr Tyr Ala Arg Arg Xaa Xaa Asp Gln Ile Val Pro Glu Tyr 
            20                  25                  30  


<210> 124
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (9)..(9)
<223> S-pentenyl alanine 

<220>
<221> MOD_RES
<222> (13)..(13)
<223> S-pentenyl alanine 

<220>
<221> MOD_RES
<222> (22)..(22)
<223> Aminohexanoic acid 

<400> 124
Ile Trp Ile Ala Gln Glu Leu Arg Xaa Ile Gly Asp Xaa Phe Asn Ala 
1               5                   10                  15      


Tyr Tyr Ala Arg Arg Xaa Asp Gln Ile Val Pro Glu Tyr 
            20                  25                  


<210> 125
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"


<220>
<221> MOD_RES
<222> (8)..(8)
<223> Aminohexanoic acid 

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Aminohexanoic acid 

<220>
<221> MOD_RES
<222> (18)..(18)
<223> S-pentenyl alanine 

<220>
<221> MOD_RES
<222> (22)..(22)
<223> S-pentenyl alanine 

<400> 125
Asp Gln Ile Val Pro Glu Tyr Xaa Xaa Ile Trp Ile Ala Gln Glu Leu 
1               5                   10                  15      


Arg Xaa Ile Gly Asp Xaa Phe Asn Ala Tyr Tyr Ala Arg Arg 
            20                  25                  30  


<210> 126
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (8)..(8)
<223> Aminohexanoic acid 

<220>
<221> MOD_RES
<222> (17)..(17)
<223> S-pentenyl alanine 

<220>
<221> MOD_RES
<222> (21)..(21)
<223> S-pentenyl alanine 

<400> 126
Asp Gln Ile Val Pro Glu Tyr Xaa Ile Trp Ile Ala Gln Glu Leu Arg 
1               5                   10                  15      


Xaa Ile Gly Asp Xaa Phe Asn Ala Tyr Tyr Ala Arg Arg 
            20                  25                  


<210> 127
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (5)..(5)
<223> DAB-thalidomide, DAB-Gly-Thal, DAB-beta-Ala-Thal, DAB-Linker1-
      Thal, DAB-Linker2-Thal, DAB-Linker3-Thal, DAB-Linker4-Thal, 
      DAB-Linker5-Thal, DAB-Linker6-Thal, DAB-Linker7-Thal, or 
      DAB-Linker8-Thal 

<220>
<221> MOD_RES
<222> (9)..(9)
<223> (S)-2-(4-pentenyl)alanine 

<220>
<221> MOD_RES
<222> (13)..(13)
<223> (S)-2-(4-pentenyl)alanine 

<400> 127
Ile Trp Ile Ala Xaa Glu Leu Arg Xaa Ile Gly Asp Xaa Phe Asn Ala 
1               5                   10                  15      


Tyr Tyr Ala Arg Arg 
            20  


<210> 128
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (9)..(9)
<223> (S)-2-(4-pentenyl)alanine

<220>
<221> MOD_RES
<222> (13)..(13)
<223> (S)-2-(4-pentenyl)alanine

<220>
<221> MOD_RES
<222> (16)..(16)
<223> DAB-thalidomide, DAB-Gly-Thal, DAB-beta-Ala-Thal, DAB-Linker1-
      Thal, DAB-Linker2-Thal, DAB-Linker3-Thal, DAB-Linker4-Thal, 
      DAB-Linker5-Thal, DAB-Linker6-Thal, DAB-Linker7-Thal, or 
      DAB-Linker8-Thal 

<400> 128
Ile Trp Ile Ala Gln Glu Leu Arg Xaa Ile Gly Asp Xaa Phe Asn Xaa 
1               5                   10                  15      


Tyr Tyr Ala Arg Arg 
            20      


<210> 129
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> (R)-2-(7-octenyl)alanine 

<220>
<221> MOD_RES
<222> (5)..(5)
<223> DAB-thalidomide, DAB-Gly-Thal, DAB-beta-Ala-Thal, DAB-Linker1-
      Thal, DAB-Linker2-Thal, DAB-Linker3-Thal, DAB-Linker4-Thal, 
      DAB-Linker5-Thal, DAB-Linker6-Thal, DAB-Linker7-Thal, or 
      DAB-Linker8-Thal; continued below;

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Continued from above; DAB-TRIB carboxylate, DAB-Gly-TRIB 
      carboxylate, DAB-beta-Ala-TRIB carboxylate, DAB-Linker3-
      TRIB carboxylate, DAB-Linker5-TRIB carboxylate, DAB-Linker7-
      TRIB carboxylate

<220>
<221> MOD_RES
<222> (11)..(11)
<223> (S)-2-(4-pentenyl)alanine 

<400> 129
Leu Thr Phe Xaa Xaa Tyr Trp Ala Gln Leu Xaa Ser Ala Ala 
1               5                   10                  


<210> 130
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> (R)-2-(7-octenyl)alanine 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> (S)-2-(4-pentenyl)alanine 

<220>
<221> MOD_RES
<222> (12)..(12)
<223> DAB-thalidomide, DAB-Gly-Thal, DAB-beta-Ala-Thal, DAB-Linker1-
      Thal, DAB-Linker2-Thal, DAB-Linker3-Thal, DAB-Linker4-Thal, 
      DAB-Linker5-Thal, DAB-Linker6-Thal, DAB-Linker7-Thal, or 
      DAB-Linker8-Thal; continued below; 

<220>
<221> MOD_RES
<222> (12)..(12)
<223> Continued from above; DAB-VHL carboxylate, DAB-Gly-VHL 
      carboxylate, DAB-beta-Ala-VHL carboxylate, DAB-Linker3-VHL
      carboxylate, DAB-Linker5-VHL carboxylate, and DAB-Linker7-VHL
      carboxylate

<400> 130
Leu Thr Phe Xaa Glu Tyr Trp Ala Gln Leu Xaa Xaa Ala Ala 
1               5                   10                  


<210> 131
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> DAB-thalidomide, DAB-Gly-Thal, DAB-beta-Ala-Thal, DAB-Linker1-
      Thal, DAB-Linker2-Thal, DAB-Linker3-Thal, DAB-Linker4-Thal, 
      DAB-Linker5-Thal, DAB-Linker6-Thal, DAB-Linker7-Thal, or 
      DAB-Linker8-Thal; continued below; 

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Continued from above; DAB-VHL carboxylate, DAB-Gly-VHL 
      carboxylate, DAB-beta-Ala-VHL carboxylate, DAB-Linker3-VHL
      carboxylate, DAB-Linker5-VHL carboxylate, and DAB-Linker7-VHL
      carboxylate 

<220>
<221> MOD_RES
<222> (4)..(4)
<223> (R)-2-(7-octenyl)alanine 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> (S)-2-(4-pentenyl)alanine 

<400> 131
Xaa Thr Phe Xaa Glu Tyr Trp Ala Gln Leu Xaa Ser Ala Ala 
1               5                   10                  


<210> 132
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (10)..(10)
<223> Cyclobutylalanine 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> S-pentenyl alanine 

<400> 132
Leu Thr Phe Xaa Glu Tyr Trp Ala Gln Xaa Xaa Ser Ala Ala 
1               5                   10                  


<210> 133
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (9)..(9)
<223> (S)-2-(4-pentenyl)alanine

<220>
<221> MOD_RES
<222> (13)..(13)
<223> (S)-2-(4-pentenyl)alanine

<220>
<221> MOD_RES
<222> (19)..(19)
<223> Norleucine 

<400> 133
Gln Leu Thr Ala Ala Arg Leu Lys Xaa Leu Gly Asp Xaa Leu His Gln 
1               5                   10                  15      


Arg Thr Xaa Trp Arg 
            20      


<210> 134
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> S-pentenyl alanine 

<400> 134
Leu Thr Phe Xaa Glu Tyr Trp Ala Gln Leu Xaa Ser Ala Ala 
1               5                   10                  


<210> 135

<400> 135
000


<210> 136
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (5)..(5)
<223> DAB-thalidomide, DAB-Gly-Thal, DAB-beta-Ala-Thal, DAB-Linker1-
      Thal, DAB-Linker2-Thal, DAB-Linker3-Thal, DAB-Linker4-Thal, 
      DAB-Linker5-Thal, DAB-Linker6-Thal, DAB-Linker7-Thal, or 
      DAB-Linker8-Thal 

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (13)..(13)
<223> Any amino acid

<400> 136
Ile Trp Ile Ala Xaa Glu Leu Arg Xaa Ile Gly Asp Xaa Phe Asn Ala 
1               5                   10                  15      


Tyr Tyr Ala Arg Arg 
            20      


<210> 137
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (9)..(9)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (13)..(13)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (16)..(16)
<223> DAB-thalidomide, DAB-Gly-Thal, DAB-beta-Ala-Thal, DAB-Linker1-
      Thal, DAB-Linker2-Thal, DAB-Linker3-Thal, DAB-Linker4-Thal, 
      DAB-Linker5-Thal, DAB-Linker6-Thal, DAB-Linker7-Thal, or 
      DAB-Linker8-Thal 

<400> 137
Ile Trp Ile Ala Gln Glu Leu Arg Xaa Ile Gly Asp Xaa Phe Asn Xaa 
1               5                   10                  15      


Tyr Tyr Ala Arg Arg 
            20      


<210> 138
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (5)..(5)
<223> DAB-TRIB carboxylate, DAB-Gly-TRIB carboxylate, 
      DAB-beta-Ala-TRIB carboxylate, DAB-Linker3-TRIB 
      carboxylate, DAB-Linker5-TRIB carboxylate, 
      DAB-Linker7-TRIB carboxylate

<220>
<221> MOD_RES
<222> (11)..(11)
<223> S-pentenyl alanine 

<400> 138
Leu Thr Phe Xaa Xaa Tyr Trp Ala Gln Leu Xaa Ser Ala Ala 
1               5                   10                  


<210> 139
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> S-pentenyl alanine 

<220>
<221> MOD_RES
<222> (12)..(12)
<223> DAB-TRIB carboxylate, DAB-Gly-TRIB carboxylate, 
      DAB-beta-Ala-TRIB carboxylate, DAB-Linker3-TRIB 
      carboxylate, DAB-Linker5-TRIB carboxylate, 
      DAB-Linker7-TRIB carboxylate

<400> 139
Leu Thr Phe Xaa Glu Tyr Trp Ala Gln Leu Xaa Xaa Ala Ala 
1               5                   10                  


<210> 140
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> DAB-thalidomide, DAB-Gly-Thal, DAB-beta-Ala-Thal, DAB-Linker1-
      Thal, DAB-Linker2-Thal, DAB-Linker3-Thal, DAB-Linker4-Thal, 
      DAB-Linker5-Thal, DAB-Linker6-Thal, DAB-Linker7-Thal, or 
      DAB-Linker8-Thal 

<220>
<221> MOD_RES
<222> (4)..(4)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> S-pentenyl alanine 

<400> 140
Xaa Thr Phe Xaa Glu Tyr Trp Ala Gln Leu Xaa Ser Ala Ala 
1               5                   10                  


<210> 141
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (5)..(5)
<223> DAB-thalidomide, DAB-Gly-Thal, DAB-beta-Ala-Thal, DAB-Linker1-
      Thal, DAB-Linker2-Thal, DAB-Linker3-Thal, DAB-Linker4-Thal, 
      DAB-Linker5-Thal, DAB-Linker6-Thal, DAB-Linker7-Thal, or 
      DAB-Linker8-Thal 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> S-pentenyl alanine 

<400> 141
Leu Thr Phe Xaa Xaa Tyr Trp Ala Gln Leu Xaa Ser Ala Ala 
1               5                   10                  


<210> 142
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(4)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> S-pentenyl alanine 

<220>
<221> MOD_RES
<222> (12)..(12)
<223> DAB-thalidomide, DAB-Gly-Thal, DAB-beta-Ala-Thal, DAB-Linker1-
      Thal, DAB-Linker2-Thal, DAB-Linker3-Thal, DAB-Linker4-Thal, 
      DAB-Linker5-Thal, DAB-Linker6-Thal, DAB-Linker7-Thal, or 
      DAB-Linker8-Thal 

<400> 142
Leu Thr Phe Xaa Glu Tyr Trp Ala Gln Leu Xaa Xaa Ala Ala 
1               5                   10                  


<210> 143
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (1)..(1)
<223> DAB-VHL carboxylate, DAB-Gly-VHL carboxylate, 
      DAB-beta-Ala-VHL carboxylate, DAB-Linker3-VHL 
      carboxylate, DAB-Linker5-VHL carboxylate, and 
      DAB-Linker7-VHL carboxylate

<220>
<221> MOD_RES
<222> (4)..(4)
<223> R-octenyl alanine 

<220>
<221> MOD_RES
<222> (11)..(11)
<223> S-pentenyl alanine 

<400> 143
Xaa Thr Phe Xaa Glu Tyr Trp Ala Gln Leu Xaa Ser Ala Ala 
1               5                   10                  


<210> 144
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> source 
<223> /note="N-term Acetylated"
 
<220>
<221> MOD_RES
<222> (9)..(9)
<223> (S)-2-(4-pentenyl)alanine 

<220>
<221> MOD_RES
<222> (13)..(13)
<223> (S)-2-(4-pentenyl)alanine 

<220>
<221> MOD_RES
<222> (22)..(22)
<223> Lys-degron 

<400> 144
Ile Trp Ile Ala Gln Glu Leu Arg Xaa Ile Gly Asp Xaa Phe Asn Ala
1               5                   10                  15      


Tyr Tyr Ala Arg Arg Xaa 
            20              


<210> 145
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 145
Asp Ser Gly Ile His Ser 
1               5       


